Vor Biopharma Inc.
VOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817229
In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $908.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $4.21K in total
- 1
- 13F holdersQ2 2026, +22 vs. previous quarter
- 102
- 13F valueReported value at the end of Q2 2026
- $908.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding VOR, Q2 2026
No superinvestor reported holding VOR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Vor Biopharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2026 (view filing)4:54 PM ET | Jul 16 | 5 daysLate | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −213 | $19.75 | −$4.21K | 0.0%4.50M after | |
| Apr 24, 2026 (view filing)6:12 PM ET | Apr 22 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −165.2K | $15.77 | −$2.60M | −6.4%2.40M after | |
| Apr 21, 2026 (view filing)7:04 PM ET | Apr 17-20 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −630.4K | $16.14 | −$10.2M | −19.7%2.57M after | 2 lots |
| Apr 15, 2026 (view filing)5:29 PM ET | Apr 13-15 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −738.0K | $16.10 | −$11.9M | −18.8%3.20M after | 3 lots |
| Apr 10, 2026 (view filing)6:23 PM ET | Apr 8-10 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −620.1K | $16.50 | −$10.2M | −13.6%3.94M after | 4 lots |
| Apr 6, 2026 (view filing)6:51 PM ET | Apr 2-6 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −849.3K | $17.10 | −$14.5M | −15.7%4.56M after | 5 lots |
| Oct 30, 2025 (view filing)6:40 PM ET | Oct 28-30 | 2 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −400.4K | $25.90 | −$10.4M | −33.9%779.7K after | 4 lots |
| Oct 27, 2025 (view filing)8:04 PM ET | Oct 23-27 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | SSale | −221.2K | $28.06 | −$6.20M | −15.8%1.18M after | 3 lots |
| Oct 22, 2025 (view filing)7:48 PM ET | Oct 20-21 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | SSale | −117.0K | $29.34 | −$3.43M | −7.7%1.40M after | 5 lots |
| Oct 21, 2025 (view filing)5:45 PM ET | Oct 17-21 | 4 days | Hoffman Reid and 1 other10% Owner | SSale | −37.5K | $30.19 | −$1.13M | −3.1%1.17M after | 4 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Vor Biopharma Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 5,673,078 | $104.4M | 2.51% | 00.0% | Unchanged |
| FMR LLC | 4,932,149 | $90.8M | 0.00% | +3,392,479+220.3% | Added |
| FCPM III Services B.V. | 4,117,354 | $75.8M | 10.10% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,468,107 | $63.8M | 0.00% | +2,673,348+336.4% | Added |
| VR Adviser, LLC | 3,041,719 | $56.0M | 1.70% | 00.0% | Unchanged |
| State Street Corp | 2,616,336 | $48.2M | 0.00% | +1,497,878+133.9% | Added |
| Frazier Life Sciences Management, L.P. | 2,543,939 | $46.8M | 1.02% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 2,402,095 | $44.2M | 0.38% | −3,002,903−55.6% | Reduced |
| Vanguard Capital Management LLC | 2,084,328 | $38.4M | 0.00% | +651,048+45.4% | Added |
| Caligan Partners LP | 1,925,066 | $35.4M | 1.71% | 00.0% | Unchanged |